NCT01161511已完成1 期
A Phase 1 Study of XmAb®5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Xencor, Inc.
- 入组人数
- 27
- 试验地点
- 3
- 主要终点
- To determine the dose limiting toxicities
研究概览
简要总结
This is an open-label, multi-dose, single-arm, Phase 1, dose-escalation study of XmAb5574. The study was conducted to identify the maximum tolerated dose (MTD) and/or recommended dose(s) (RD) for further study, to characterize safety and tolerability, to characterize PK, PD and immunogenicity, and to evaluate preliminary antitumor activity of XmAb5574 in patients with relapsed or refractory CLL/SLL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •relapsed or refractory CLL/SLL
- •at least 18 years of age
- •able to receive outpatient treatment and follow-up at the treating institution
- •completed all CLL therapies > 4 weeks prior to first study dose
排除标准
- •previously treated with an anti-CD19 antibody therapy
- •undergone prior allogeneic stem cell transplantation within 6 months or having active graft versus host disease
- •active Richter's syndrome
- •designated Class III or IV by the New York Heart Association (NYHA) criteria
- •history of myocardial infarction or stroke within the last 6 months
- •active viral, bacterial, or systemic fungal infection requiring treatment
- •HIV or Hepatitis C positive
- •Hepatitis B infection
研究组 & 干预措施
1
Experimental
XmAb5574
干预措施: XmAb5574 (Biological)
结局指标
主要结局
To determine the dose limiting toxicities
时间窗: 28 days
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
招募中
1 期
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsOvarian CancerGerm Cell TumorEndometrial CancerOvarian Germ Cell TumorTesticular Germ Cell TumorNCT06276491Xencor, Inc.282
已完成
2 期
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)IgG4-RDNCT02725476Xencor, Inc.20
终止
1 期
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic DermatitisPsoriasisAtopic DermatitisNCT06005792Xencor, Inc.23
招募中
1 期
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaClear Cell Renal Cell CarcinomaNCT05433142Xencor, Inc.307
已完成
1 期
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell LymphomaHodgkin LymphomaAnaplastic Large Cell LymphomaNCT00606645Xencor, Inc.23